ArticleAnalytical chemistry2026
Parallel Sequencing of the Two Arms on a Bispecific Antibody by Electron Capture Dissociation on a timsOmni Platform Reveals Several By-products in the Controlled Fab-arm Exchange Process.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bispecific antibodies (bsAbs) can simultaneously target two distinct antigens, offering enhanced therapeutic efficacy compared to conventional antibodies. However, their complex manufacturing process, involving pairing of four distinct polypeptide chains (two heavy and two light chains), enhances the analytical challenges in quality control. Here, we applied top-down mass spectrometry using electron capture dissociation (ECD) on a novel timsOmni platform to characterize the bsAb LaC49 (AR4A/AR3C) and its monospecific precursors, IgG1-AR4A and IgG1-AR3C. This bsAb was developed to target different epitopes of the E1E2 envelope glycoprotein on the surface of hepatitis C virus (HCV). The bsAb was prepared via controlled Fab-arm exchange. Native mass spectrometry revealed that the sample contained the intended bsAb but also products that displayed substantial structural heterogeneity, including residual monospecific IgG1-AR4A and multiple other mass variants. ECD MS/MS analysis of the F(ab')
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.